🇺🇸

US SEC Filing Intelligence

· daily

Contract Deobligations Alert — May 14, 2026

This Contract Deobligations Alert covers 11 civilian agency contracts totaling $1,643,975,470 in obligations, with 0 defense-related awards despite one DOD construction contract to S. J. Amoroso Construction Co., LLC for $176.9M. Dominant themes include large-scale construction projects led by Department of State ($778.7M across Caddell Construction and Acuity-CHS) and facilities recapitalization under DHS/Coast Guard. Highest-conviction bullish signal is Caddell Construction Co. (DE), LLC's $698M firm fixed price office building contract through 2027, signaling major State commitment. Key risk is widespread $0 outlays on high-materiality awards like Caddell ($698M), Whiting-Turner ($132M), and Booz Allen Hamilton ($79M), alongside firm fixed price exposure on 6 contracts amplifying execution risks.

11 total filings
· daily

Contract Option Exercises — May 14, 2026

These 11 contract option exercises total $1,643,975,470 in obligations, with 0/11 defense-related despite one DOD award to S. J. Amoroso Construction Co., LLC ($176.96M), highlighting a purely civilian-focused stream dominated by construction projects from State ($698M Caddell), DOD ($177M Amoroso), and DHS ($132M Whiting-Turner). Highest-conviction bullish signals emerge from large firm-fixed-price construction commitments to Caddell Construction Co. (DE), LLC ($698M office buildings) and S. J. Amoroso ($177M), signaling multi-year revenue visibility through 2027. Neutral signals prevail on IT/engineering awards to Booz Allen Hamilton ($79M GSA, potential $340M) and others, tempered by high firm-fixed-price risks and $0 outlays on top materiality contracts. Key risk: Monitor outlay progress from $0 on $1.3B+ (e.g., Caddell, Whiting-Turner) amid firm-fixed-price exposure and CR vulnerability for recent awards.

11 total filings
· daily

Federal Professional Services Contracts — May 14, 2026

Two civilian federal professional services contracts totaling $140,932,011 in obligations were analyzed, with 0/2 defense-related and an average signal strength of 6.0/10. Booz Allen Hamilton's $79,261,970 GSA delivery order for NEBULA engineering services dominates by materiality, offering bullish exposure to a $340,084,820 potential value including options, while Noblis's $61,670,041 DHS order for SETA support shows neutral steady execution with $46,000,714 already outlayed. The dominant theme is civilian agency demand for engineering (NAICS 541330) and management consulting (NAICS 541611) services via full and open competition. Highest-conviction signal is bullish on Booz Allen Hamilton due to its scale and low pricing risk. Key watch item is Booz Allen's $0 outlays to date amid $71,529,507 in subawards, limiting near-term prime revenue realization.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — May 14, 2026

Two civilian federal IT contracts totaling $196,095,865 in obligations highlight steady but neutral revenue streams for private small businesses V3GATE, LLC ($133.9M from VA) and ITC FEDERAL, LLC ($62.2M from DHS/ICE), with zero defense exposure. Dominant themes center on VA Technology Acquisition Center and DHS Immigration and Customs Enforcement IT support services, including VMware software maintenance and IT platform sustainment. Highest-conviction signals are neutral at 4/10 strength, reflecting significant outlays ($81.7M for V3GATE and $45.7M for ITC) amid firm fixed price structures. Key risks include high pricing execution risks on these multi-year awards running through 2026-2027. Investors should watch option exercises toward V3GATE's $137M ceiling and ITC's $80M ceiling for potential revenue upside.

2 total filings
· daily

NASA & Space Contracts Intelligence — May 14, 2026

NASA obligations totaled $63,135,880 across 1 contract in the May 14, 2026 period, representing a fully civilian split with 0/1 defense-related awards. McCallie Associates, Inc. received the sole award from NASA Goddard Space Flight Center for $63,135,880 in mission systems engineering services, emphasizing GN&C systems under an 8(a) set-aside with a $298,000,000 ceiling through 2028-11-30. The dominant agency theme is NASA commitment to small disadvantaged 8(a) firms for specialized space R&D engineering (NAICS 541715, PSC R425). Highest-conviction signal is neutral (strength 4/10), driven by $51,698,175 outlays but offset by 115 subawards totaling $136,578,636 exceeding obligations. Key watch item: outlay progress beyond $51,698,175 and option exercises toward the $298,000,000 ceiling.

1 total filings
· daily

All HHS Contracts — May 14, 2026

HHS awarded a single contract totaling $68,359,692 in obligations to Pfizer Inc through BARDA for biotechnology R&D, comprising 100% civilian spending with zero defense-related activity during the May 14, 2026 period. The dominant agency theme is HHS/BARDA's long-term health preparedness investments via a 2015 cost-no-fee contract performing through September 30, 2025. The highest-conviction signal is neutral (strength 3/10), reflecting a sustained but low-burn commitment with only $18,678,022 outlayed against $68M obligated over nearly 10 years. A key risk is the nearing contract end date and unexercised $25M options, warranting monitoring of cumulative outlays versus obligations.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 14, 2026

These four civilian mega contracts total $1,140,800,350 in obligations with 0/4 defense-related, dominated by construction awards to Caddell Construction ($698M Dept of State office buildings), S.J. Amoroso ($177M DoD), and Whiting-Turner ($132M DHS Coast Guard pier recapitalization), alongside V3Gate's $134M VA VMware IT support. The highest-conviction bullish signal is Caddell's $698M firm fixed price award under full and open competition, signaling strong positioning in institutional construction through 2027. All contracts carry high firm fixed price execution risks, with $0 outlayed to date on the three largest ($698M + $177M + $132M), warranting close monitoring of funding progress amid early-stage obligations.

4 total filings
· daily

All DOD Contracts — May 14, 2026

Over the period May 14, 2026 to May 14, 2026, a single DOD contract obligated $176,962,279, representing 1/1 defense-related awards with no civilian split. The Department of Defense is the dominant agency, awarding the entirety to S. J. AMOROSO CONSTRUCTION CO., LLC in a bullish signal tied to construction needs. The highest-conviction signal is the $177M award (materiality 8/10, strength 7/10), indicating potential infrastructure expansion. Unknown competition and pricing risk introduce execution uncertainty, particularly with the December 11, 2024 award timing vulnerable to Continuing Resolution (CR) disruptions. Investors should watch S. J. AMOROSO for follow-on task orders amid NDAA-aligned priorities.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 14, 2026

These 11 high-value civilian federal contracts total $1,643,975,470 in obligations, with 0/11 classified as defense-related despite one Department of Defense award to S.J. Amoroso Construction ($176.96M), emphasizing construction and services across State, DHS, VA, and other agencies. Dominant themes include large-scale construction projects led by Caddell Construction's $698M State Department office building contract (bullish, materiality 8/10) through 2027. Highest-conviction signal is bullish on Booz Allen Hamilton's $79.3M GSA engineering delivery order with $340M potential under cost-plus structure. Key risk is high firm-fixed-price exposure in top awards like Caddell ($698M) and Whiting-Turner ($131.9M), coupled with $0 outlays in several large contracts signaling early-stage funding vulnerabilities.

11 total filings
· daily

General Federal Contracts — May 14, 2026

These 11 civilian contracts total $1,643,975,470 in obligations with 0/11 defense-related, dominated by construction awards from Department of State ($698M to Caddell), DoD ($177M to S.J. Amoroso), DHS ($132M to Whiting-Turner), and Interior ($88M to TEPA EC). Highest-conviction bullish signal is Caddell Construction's $698M firm fixed price office building contract through 2027, signaling major State commitment despite $0 outlayed. Other bullish wins for S.J. Amoroso ($177M DoD), Whiting-Turner ($132M DHS pier recapitalization), and Booz Allen Hamilton ($79M GSA engineering, potential $340M). Key risk is high firm fixed price execution exposure on top construction awards with $0 outlays on Caddell, Whiting-Turner, and others. Watch outlay progress and option exercises amid average signal strength of 4.9/10.

11 total filings
· daily

All NASA Contracts — May 14, 2026

NASA obligated $63,135,880 to McCallie Associates, Inc. for mission systems engineering services at Goddard Space Flight Center, comprising a fully civilian contract stream (0/1 defense-related). This 8(a) set-aside award, with a base + options ceiling of $298,000,000 through November 30, 2028, has $51,698,175 already outlayed and 115 subawards totaling $136,578,636. The dominant agency theme is NASA's prioritization of small disadvantaged, tribally-owned firms in specialized GN&C systems engineering under NAICS 541715. The highest-conviction signal is neutral (4/10 strength), reflecting significant commitment but unexercised options and subcontracting reliance. A key watch item is outlay progression beyond $51.7M alongside subaward spending versus obligations.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 14, 2026

Across 41 filings in the USA S&P 500 Technology stream, a dominant theme is robust revenue acceleration in select tech, space, and comms firms (e.g., Applied Materials +11% YoY to $7.91B, Intuitive Machines 3x YoY to $186.7M, GameSquare +95% YoY to $14.5M), contrasted by profitability volatility and cash burn pressures amid M&A (Iridium $366.7M Aireon deal, Intuitive $800M Lanteris). Period-over-period trends show 7/15 quarterly reporters posting YoY revenue growth averaging +55% (outliers: ImmuCell +28%, RideNow +6.4%), but 6/15 saw net losses widen or emerge (avg -45% net income swing), with margins mixed (Applied +80bps to 49.9%, ImmuCell +340bps to 45%). Institutional 13F snapshots reveal concentrated tech bets (Broadcom $250M Paradigm, Analog Devices $216M Timucuan, TSMC/Amazon ~$20M H Squared), signaling conviction in semis/AI/cloud. Forward-looking catalysts cluster in Q3 2026 (Applied rev ~$8.95B, Iridium deal close), while capital allocation leans shareholder-friendly (Applied div +15% to $0.53). Biotech-adjacent tech like INmune Bio's FDA Fast Track adds upside, but BDC/niche declines (Muzinich income -38% YoY) flag sector divergence. Overall, actionable alpha in growth outperformers pre-earnings/M&A closes, with risks in cash-strapped turnarounds.

13 high priority 28 medium 41 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 14, 2026

The 48 filings from NASDAQ-100 constituents and related entities reveal mixed Q1 2026 results across 15 earnings reporters, with 8/15 showing YoY revenue growth averaging +28% (e.g., ImmuCell +28%, INBS +46%, Intuitive Machines +200%), but persistent net losses in 12/15 amid rising G&A/exploration costs; margin expansions noted in 4/15 (e.g., INBS +370 bps gross margin). Key themes include accretive M&A (Iridium-Aireon adding $100M rev, Intuitive Machines-Lanteris boosting backlog to $1.1B), regulatory wins (TMC NOAA compliance by Q1 2027, INmune Bio FDA Fast Track), and institutional positioning via 13Fs favoring mining/tech (e.g., Mudita heavy in gold/mining, Paradigm in semis). Capital allocation leans conservative with dividend hikes (Applied Materials +15% to $0.53/share) but no buybacks noted; cash burns improved in 6/15 ops cash flow metrics. Portfolio-level trends show metals/biotech outperformance in milestones vs. services revenue softness (Intellinetics -8%). Forward catalysts cluster in H2 2026 (deal closes, trial data), signaling alpha in space/mining amid AI/semicon strength. Overall, bullish on strategic progress offsetting losses, with watch for cash runway in microcaps.

19 high priority 29 medium 48 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 14, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related SPACs/BDCs), dominant themes include SPAC quarterly resilience via trust interest income (10 SPACs averaging +$1.4M net income Q1 2026 despite ops losses and cash burns QoQ 20-67%), active debt markets with refinancings/upsizes (Lumen $2.4B Term B-5, Encore €325M notes), and mixed operating results in financial-adjacent firms (revenue growth in 8/15 ops cos avg +45% YoY skewed by small caps like Lifeway +37%, Karman +51%, but declines in larger like New Fortress -52%, Apartment REIT -4.8%). Period-over-period trends reveal margin expansions in outliers (Lifeway +360bps, Intelligent Bio +380bps to 50.5%) contrasting compressions elsewhere (SpringBig gross -16.8%), with capital allocation favoring debt raises over buybacks/dividends (News Corp $1B program ongoing, Muzinich no distributions). Forward-looking signals positive for growth (Lifeway FY2027 EBITDA $45-50M, Health In Tech scaling in $1T market), but SPAC risks high (Cantor 22M shares redeemed -$234M trust, Vernal going concern). Portfolio-level: Neutral 13Fs (Lord Abbett $30M, Gemsstock $949M energy tilt), bullish catalysts in M&A (Presidio $83M oil/gas), bearish cash burns signal caution; actionable now: Favor debt-access firms, monitor SPAC combos.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 14, 2026

Across 50 filings primarily from small-cap biotechs, medtech, financials, and institutional 13F-HR snapshots (despite Consumer Staples stream focus, data skews pharma/services), Q1 2026 results show mixed performance: 8/15 quarterly reporters achieved revenue growth averaging +28% YoY (e.g., Intelligent Bio +46%, NIQ +11.1%), but 12/15 widened net losses (avg +45% YoY) amid rising opex/R&D, with cash burn improving in 6 cases. Key themes include M&A completion (Apellis acquired by Biogen at $41/share + CVR), positive clinical data (Cellectar 61.8% MRR), financing successes ($140M for Cellectar, $50M loan for Pelthos), and neutral 13F holdings in tech/ETFs signaling steady institutional conviction. Capital allocation leans defensive (dividends at Chicago BDC $0.34/share, reverse splits at Reliance), with forward guidance reaffirmed (NIQ 5-5.3% OCC growth). Portfolio-level trends: margin expansion in 4/10 (Intelligent Bio +380bps), but compression elsewhere; biotech outliers shine on milestones vs deteriorating liquidity in 7 firms (cash down >50% QoQ). Implications: tactical opportunities in catalysts (ASCO June 1), but watch liquidity risks and delistings amid volatile small-caps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 14, 2026

Across the 50 filings in the USA S&P 500 Industrials stream, sentiment skews mixed-positive, driven by robust revenue growth in select industrials and energy-adjacent names like Forgent Power Solutions (+103% YoY to $379M revenue, +308% bookings) and LanzaTech (+26% YoY revenue), contrasting with persistent net losses in biotechs despite R&D progress. Period-over-period trends reveal 8/18 quarterly reporters with YoY revenue growth averaging 52% (outliers: Forgent 103%, Intelligent Bio 46%), but 10/18 showed net loss widening (avg +35% YoY) due to OpEx ramps; margins expanded in 5 cases (e.g., Forgent Adj EBITDA +96% to 22.4%). Institutional 13Fs (17 filings) highlight concentrated ETF exposure and defense industrials like Lockheed Martin ($10.5M in Campion), signaling broad sector conviction. Capital allocation shines with CSX's $5B buyback authorization atop $989M remaining, while M&A (Apellis acquired at $41/share + CVR) and debt raises (Constellation $2.2B notes) bolster liquidity. Forward-looking data flags raised guidances (Forgent FY26 rev +82% YoY midpoint, Hyperion +20%) and catalysts like Cabaletta's mid-2026 data readouts. Portfolio implications: Tactical buys in high-growth industrials amid biotech volatility, monitor June 2026 debt events.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 14, 2026

The S&P 500 Energy sector filings reveal strong shareholder confidence in governance at majors ConocoPhillips and Phillips 66, with near-unanimous approvals for directors, auditors, and exec comp amid rejected independent chair proposal at COP. A wave of 13F-HR disclosures from institutions like Blue Whale Capital ($2.1B portfolio, NVIDIA/Lam top), Fuller & Thaler ($29.7B, industrials focus), and Noked Israel ($677M, semis heavy) shows minimal evident energy exposure in top holdings, suggesting investor sidelining of oil/gas amid tech preference. Apartment Income REIT's Q1 10-Q flags mixed results: revenues -4.8% YoY to $193.7M, net loss $(28.9M) vs prior profit, but operating cash +376% YoY to $39.6M and interest expense -13.5% to $81.2M. No insider trades, M&A, or guidance changes noted across filings; capital allocation subdued with REIT capex -48% YoY to $12.8M. Portfolio-level trend: neutral institutional positioning, positive energy AGM outcomes contrast REIT weakness, implying stable but uninspiring sector momentum into Q2 2026.

2 high priority 10 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — May 14, 2026

Across 50 8-K filings from May 14, 2026, dominant themes include a surge in debt refinancings and issuances totaling over $15B (e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B), signaling robust capital market access amid favorable rates and extending maturities out to 2036. M&A activity highlights consolidation with Apellis Pharmaceuticals fully acquired by Biogen at $41/share + CVR, Iridium's accretive $367M Aireon buy adding $100M annualized revenue, and Presidio's $83M Oklahoma assets deal closing Q3 2026. Leadership transitions are orderly (e.g., RenaissanceRe CFO succession, Selective Insurance CIO retirement), with positive capital returns via CSX's $5B buyback and KeyCorp's $3B program + dividends. Limited period-over-period data shows NeoVolta's nine-month revenue +262% YoY to $13.3M but Q3 flat YoY at $2M and wider $3M net loss, amid residential solar slowdown. Risks cluster in dilutive financings (HyOrc, GridAI) and restructurings (Trinseo's $2B debt cut via Chapter 11), while opportunities emerge in energy acquisitions and SPAC extensions. Sector patterns favor utilities/energy refinancing for balance sheet strength, contrasting mixed sentiment in small-cap tech financings.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 14, 2026

Across 50 SEC filings from May 14, 2026, primarily Q1 2026 10-Qs and 8-Ks, a key theme is robust revenue growth in 12/20 reporting companies averaging 67% YoY (e.g., RenovoRx +186%, Barfresh +92%, Aveanna +15.9%), driven by commercial expansion and segment gains, though offset by widening losses in 8 cases due to rising SG&A/R&D (avg +25% YoY). Biotech and healthcare firms dominate with clinical catalysts (e.g., Corvus Phase 1 success, RenovoRx trial enrollment by June), while telecom (Verizon) and consumer (YETI) show stable financing/debt access. Margin trends mixed: expansions in Enovix (+495% gross profit), compressions in YETI (-210 bps) and Versant (-11% op income). Capital allocation favors repurchases/dividends (Versant $100M buyback, YETI $500M auth increase) amid cash raises ($30M LanzaTech, $150M Cabaletta). Forward guidance raised in 4 firms (Aveanna rev +$40M, YETI sales 7-8%), signaling confidence; DJ30 exposure limited but Verizon's $4B notes positive. Portfolio implication: selective buys in growth biotechs/healthcare with near-term catalysts, caution on expense-heavy small caps; alpha from M&A/turnarounds like Kennedy-Wilson merger.

21 high priority 29 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 14, 2026

Across 50 SEC filings for May 14, 2026, Q1 2026 results reveal polarized performance: strong revenue growth in niche consumer (Lifeway +37% YoY) and biotech (Intelligent Bio +46% YoY), contrasted by sharp declines in energy (New Fortress -52% YoY revenue) and SPACs facing cash burns despite trust interest income (avg +1000% YoY in 8 SPACs). Debt refinancings (Lumen $2.4B Term B-5) and M&A (Presidio $83M oil/gas acquisition) signal financial maneuvers amid mixed sentiment (28/50 mixed/neutral). SPACs dominate with extensions (GP-Act III to Nov 2026) and deficits widening (avg 10% QoQ in 10 filings), while 13Fs highlight institutional bets on biotech/energy (Rhenman healthcare heavy, Gemsstock energy/gold). Capital allocation leans conservative with buybacks (News Corp $1B program) and dividends steady; forward guidance sparse but Lifeway targets $45-50M EBITDA FY2027. Portfolio trend: 12/25 10-Qs show revenue growth >20% YoY but margins mixed (avg +100bps in winners, -200bps losers), implying selective opportunities in growth outliers amid broader caution.

33 high priority 17 medium 50 total filings